BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
-4.07%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$8.61B
AUM Growth
-$1.09B
(-11%)
Cap. Flow
-$379M
Cap. Flow
% of AUM
-4.4%
Top 10 Holdings %
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30
Top Buys
| 1 |
Outset Medical
OM
|
$66.1M |
| 2 |
Boston Scientific
BSX
|
$42.1M |
| 3 |
CareDx
CDNA
|
$31.2M |
| 4 |
Pacific Biosciences
PACB
|
$30.3M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
$29.8M |
Top Sells
| 1 |
Biogen
BIIB
|
$106M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$81.3M |
| 3 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
$75.3M |
| 4 |
Danaher
DHR
|
$68.9M |
| 5 |
Humana
HUM
|
$68M |
Sector Composition
| 1 | Healthcare | 98.39% |
| 2 | Industrials | 0.69% |
| 3 | Energy | 0.03% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Sight Sciences
SGHT
$193M
| $3.47M | 0.04% |
300,000
| – | – |
|
127
Kosmos Energy
KOS
$784M
| $2.96M | 0.03% |
412,000
+120,000
| +41% | +$863K |
|
|
CELL
128
DELISTED
PhenomeX Inc. Common Stock
CELL
| $2.74M | 0.03% |
385,014
| – | – |
|
129
Cytokinetics
CYTK
$6.34B
| $2.54M | 0.03% |
+69,000
| New | +$2.54M |
|
130
Pfizer
PFE
$141B
| $2.41M | 0.03% |
46,500
-66,500
| -59% | -$3.44M |
|
131
Sanofi
SNY
$113B
| $2.24M | 0.03% |
+43,600
| New | +$2.24M |
|
132
Kymera Therapeutics
KYMR
$3.11B
| $2.22M | 0.03% |
52,400
+3,400
| +7% | +$144K |
|
133
Seer Inc
SEER
$118M
| $2.08M | 0.02% |
136,133
| – | – |
|
134
Cencora
COR
$56.7B
| $2.01M | 0.02% |
+13,000
| New | +$2.01M |
|
135
Alkermes
ALKS
$4.94B
| $1.97M | 0.02% |
+75,000
| New | +$1.97M |
|
136
Supernus Pharmaceuticals
SUPN
$2.58B
| $1.91M | 0.02% |
+59,000
| New | +$1.91M |
|
137
Ultragenyx Pharmaceutical
RARE
$3.07B
| $1.87M | 0.02% |
25,700
+4,700
| +22% | +$341K |
|
|
BPMC
138
DELISTED
Blueprint Medicines
BPMC
| $1.66M | 0.02% |
26,000
+500
| +2% | +$31.9K |
|
139
Pacira BioSciences
PCRX
$1.19B
| $1.61M | 0.02% |
+21,136
| New | +$1.61M |
|
|
BCYC
140
Bicycle Therapeutics
BCYC
$496M
| $1.6M | 0.02% |
36,500
-17,200
| -32% | -$755K |
|
141
C4 Therapeutics
CCCC
$194M
| $1.32M | 0.02% |
54,500
+7,300
| +15% | +$177K |
|
|
MRTX
142
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.22M | 0.01% |
14,800
-6,800
| -31% | -$559K |
|
143
Intellia Therapeutics
NTLA
$1.29B
| $1.18M | 0.01% |
16,294
-300
| -2% | -$21.8K |
|
|
GTH
144
DELISTED
Genetron Holdings Limited ADS
GTH
| $1.17M | 0.01% |
178,607
-62,439
| -26% | -$410K |
|
145
Labcorp
LH
$23.2B
| $1.12M | 0.01% |
4,947
-4,889
| -50% | -$1.11M |
|
146
Xencor
XNCR
$610M
| $1.11M | 0.01% |
41,600
-10,500
| -20% | -$280K |
|
|
INBX
147
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $1.11M | 0.01% |
49,700
-800
| -2% | -$17.8K |
|
148
Arcturus Therapeutics
ARCT
$485M
| $1.1M | 0.01% |
40,900
-700
| -2% | -$18.9K |
|
149
Kura Oncology
KURA
$713M
| $1.06M | 0.01% |
+65,980
| New | +$1.06M |
|
150
Quanterix
QTRX
$211M
| $1.04M | 0.01% |
35,704
-361,760
| -91% | -$10.6M |
|